The antimicrobial crisis: A persistent threat
Despite the perceived end of the COVID-19 pandemic, the global battle against microbial threats is far from over.
Every day, hospitals grapple with the dual challenge of treating patients while preventing the spread of superbugs – resistant strains of bacteria that have adapted to survive even the most potent antibiotics.
Essentially a killer under your fingertips, it has been calculated that an average of 1.27 million deaths a year occur due to the Antimicrobial Resistance (AMR) crisis and it is projected to reach 10 million deaths per year by 2050 according to a United Nations report.
South of the border, the Centers for Disease Control and Prevention estimates at least 2.8 million Americans contract antibiotic-resistant infections annually, with more than 35,000 fatalities.
This crisis is not limited to our shores; it’s a global issue that continues to worsen as microbes evolve faster than the development of new treatments.
Biosenta Inc.: A game changer in antimicrobial technology
Canadian company Biosenta Inc. (CSE:ZRO) is one of the few companies addressing this critical issue.
The company specializes in innovative antimicrobial products that offer environmentally friendly solutions to combat microbial growth in various materials.
Biosenta’s flagship product, Tri-Filler, represents a breakthrough in antimicrobial technology that’s worth your attention and provides long-lasting protection against a wide spectrum of bacteria, molds and fungi.
Biosenta is distinguished as the only company worldwide with technology uniquely capable of addressing the AMR crisis, positioning the company at the forefront of one of the most pressing global health challenges.
This company is at an inflection point, an exciting phase of growth offering new investors significant upside potential.
Tri-Filler: A revolutionary antimicrobial solution
Tri-Filler is not just another antimicrobial agent; it’s a comprehensive solution that integrates seamlessly into various materials, from liquid paints, porous drywall and even rock-solid cement.
Utilizing advanced encapsulated nanotechnology, Tri-Filler not only eliminates harmful microorganisms, it also enhances the strength and fire retardancy of these materials.
One of the most common fillers used industrially is calcium carbonate and like other fillers that hold moisture, it is susceptible to attracting mold. This represents a significant challenge that Tri-Filler has solved, and the multi-billion-dollar market it serves will likely take notice of this appealing alternative.
This dual functionality positions Tri-Filler as a unique product in the market, capable of providing durable antimicrobial protection while improving material performance.
A cleaner path forward
A research paper printed in the February 2024’s publication “Colloids and Surfaces A: Physicochemical and Engineering Aspects” found that BioSenta’s product represented a “more health friendly antimicrobial agent” compared with most commercially available disinfectants, which can cause serious health side effects. This study investigated controlled carbonation of Ca(OH)2 by mixing with dry ice and the use of the resultant particles as a more health friendly antimicrobial agent.
Many disinfectants are widely used despite their toxic properties and harmful effects on the ecosystem and human health. This study explored the properties of Ca(OH)2 to create particles that serve as a more health-friendly antimicrobial agent. X-ray diffraction analysis confirmed the partial carbonation of the particles.
Operational Success: Bench-scale production plant launch
Earlier this year, Biosenta finalized the construction and operation of its bench-scale production plant.
The results from this production not only exceeded the team’s expectations but also demonstrated that Tri-Filler’s antimicrobial technology is ready for accelerated development and scaling towards industrial manufacturing applications.
The plant is capable of producing up to 15 kilograms of Tri-Filler daily. This represents a substantial increase from the company’s previous reported capacity, which was limited to smaller quantities strictly for lab testing purposes.
In an exclusive interview with The Market Online’s “Watchlist,” the company’s CEO, Am Gill, explained that this elevates their transition from research and development to pilot and commercialization which will ensure industrialization.
“This allows us/Biosenta to produce Tri-Filer technology at a larger scale, paving the way for its integration into various industrial applications,” he said. “It is a crucial step forward in realizing our mission to progressively provide novel solutions and innovative steps to address global health safety and environmental changes for the public good. It’s as simple as that.”
Strategic partnerships and academic collaborations
Biosenta’s success is bolstered by strategic partnerships and collaborations with leading academic institutions. The company works closely with the University of Calgary, exclusively with the Schulich School of Engineering and the Department of Biological Sciences. This collaboration ensures that Tri-Filler undergoes rigorous testing and continuous improvement.
Recent tests have shown that Tri-Filler can effectively be integrated into lightweight concrete, significantly enhancing its strength and fire resistance.
In May 2024, Biosenta publicized its license agreement with Lightweight Concrete Solutions, which involves the use of Tri-Filler in specific specialty concrete products and a non-exclusive license for other concrete products. Under the terms of this agreement, Lightweight Concrete Solutions has agreed to pay Biosenta a significant one-time license access fee of C$200,000, along with ongoing royalties based on the sales of the licensed products, marking an important revenue milestone for the company.
Following its first industry research partnership with AMPAK Inc. a few months prior, this licensing arrangement not only highlights the unique value of Biosenta’s Tri-Filler technology but also marks its expanded application across various industry sectors, including integration into plastics.
It is a pivotal advancement in the commercialization of Tri-Filler technology as it provides immediate financial benefits through the up-front fee and ensures ongoing revenue tied to the commercial success of the products developed through this partnership.
Biosenta intends to keep working with the university to assess the performance of the plant against diverse input grades. This collaboration is crucial for refining the industrial scale plant’s optimization, paving the way for broader commercial applications of Tri-Filler technology.
It was also through these partnerships that CEO Gill believed Biosenta’s collaborative spirit was emboldened.
“We are incredibly proud to partner with a team that reflects our diverse and innovative culture,” he said in a news release. “This arrangement allows us to broaden the application of Tri-Filler within the construction industry, significantly advancing our mission to support solutions to global health challenges like antimicrobial resistance. We believe this license agreement is a testament to the versatility and effectiveness of Tri-Filler, demonstrating its potential in building materials while promoting sustainability and innovation.”
Leadership and vision
The visionary leadership of Biosenta is supported by a team of science experts, including Dr. Maen Husein, Dr. Ian Lewis, Dr. Mehdi Mohammadi Ashani, and PhD candidate Noora Naif Darwish, who together with CEO Am Gill, continue to advance the company’s mission, building on the legacy of founder Marcus Edward Martin.
Stock performance and market potential
Biosenta presents a compelling opportunity for investors. Since 2020, the company’s stock has surged more than 1,200 per cent, reflecting growing confidence in its groundbreaking technology and market potential.
In the past year alone, Biosenta’s stock has seen a remarkable increase of 109 per cent, reflecting strong and sustained investor interest. This robust market performance underscores the confidence in our innovative approach and the potential for future growth.
Environmental impact and sustainability
Biosenta is not only focused on fighting microbes but also on sustainability. The company’s production process involves capturing carbon dioxide (CO2) to create the particle used in Tri-Filler. Preliminary studies suggest that widespread use of Tri-Filler could reduce CO2 emissions by up to 10 per cent, contributing to global efforts to combat climate change.
Future prospects and industry applications
The potential applications of Tri-Filler are vast. From embedding it in smartphone cases to incorporating it into construction materials, the possibilities are endless. Imagine hospitals built with materials infused with Tri-Filler, significantly reducing the risk of hospital-acquired infections. This technology could revolutionize hygiene standards in various industries, including healthcare, food packaging and consumer goods.
The team is also looking at building an industrial scale-up plant and pledged to share more details when ready. The potential behind such a move would mean a significant boost to its production capabilities and spread its impact across multiple industries.
Investor’s corner
Biosenta Inc. stands at the intersection of innovation and necessity. As the world continues to face microbial threats, the company’s advanced antimicrobial solutions offer a glimmer of hope. With a solid leadership team, strong academic partnerships, and a commitment to sustainability, Biosenta is well-positioned to make a significant impact on global health and the environment. For investors, this represents an opportunity for financial returns, and a chance to contribute to a safer, healthier world.
For regular updates and insights, stay connected with Biosenta’s latest innovations and industry contributions visit biosenta.com and follow the company us on LinkedIn.
This is sponsored content issued on behalf of Biosenta Inc., please see full disclaimer here.
(Top image: AI-generated stock photo)
